
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is a leading medical device company with a strong portfolio of products targeted towards chronic diseases. With a large portion of sales coming from international markets and strong financials, including revenue growth of 5-7% and operating margin improvement, we believe the company is well-positioned for future success. Furthermore, recent acquisitions such as Scientia Vascular and CathWorks demonstrate Medtronic's commitment to pursuing strategic opportunities for growth and innovation.
Bears say
Medtronic is facing numerous challenges due to unsuccessful new product launches, loss of market share in certain product categories, and declining operating margins, leading to below-consensus earnings. Additionally, their recent acquisition of Scientia Vascular may not provide the desired boost to their portfolio, and their recent earnings beat was driven by currency tailwinds rather than underlying growth. However, there are potential upside drivers, such as stronger sales of new products and improved margins, which could improve the company's outlook.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares